Clovis Oncology (CLVS) Could Trade Up $8-$16 on TRITON2 44% ORR - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer (mCRPC) at ESMO 2018 Congress
October 19, 2018 6:01 AM EDT44% confirmed objective response rate (ORR) reported in 25 RECIST-evaluable patients with a BRCA1/2 alteration in initial data from ongoing TRITON2 Phase 2 study; median duration of response has not yet been reached 51% confirmed PSA response rate shown in 45 PSA-evaluable patients with a BRCA1/2 alteration Reductions in target lesion diameters and PSA measurements have been observed in patients with an ATM alteration Preliminary safety data for Rubraca in men with mCRPC are consistent with those observed in patients with ovarian cancer and other solid tumors... More
